Search

Your search keyword '"Bödder, Johanna"' showing total 12 results
Start Over Author "Bödder, Johanna"
12 results on '"Bödder, Johanna"'

1. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Rammensee, Hans-Georg, Wiesmüller, Karl-Heinz, Chandran, P. Anoop, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel J., Di Marco, Moreno, Haen, Sebastian P., Walz, Juliane S., Gloria, Yamel Cardona, Bödder, Johanna, Schertel, Jill-Marie, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander N. R., Pichler, Bernd J., Kneilling, Manfred, la Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus W.

Published
2019
Full Text
View/download PDF

4. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

Author

Le Gall, Camille, primary, Cammarata, Anna, additional, de Haas, Lukas, additional, Ramos-Tomillero, Iván, additional, Cuenca-Escalona, Jorge, additional, Schouren, Kayleigh, additional, Wijfjes, Zacharias, additional, Becker, Anouk M D, additional, Bödder, Johanna, additional, Dölen, Yusuf, additional, de Vries, I Jolanda M, additional, Figdor, Carl G, additional, Flórez-Grau, Georgina, additional, and Verdoes, Martijn, additional

Published
2022
Full Text
View/download PDF

6. MOESM7 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 7: Table S1. Induction of cytokine release by XS15. Table S2. Antibody responses to XS15.

7. MOESM7 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 7: Table S1. Induction of cytokine release by XS15. Table S2. Antibody responses to XS15.

8. MOESM1 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 1. Supplementary Materials and Methods.

9. MOESM8 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 8: Fig. S1. Impact of XS15 on slanMo-mediated T-cell polarization. Fig. S2. Impact of XS15 on slanMo-mediated IFNγ expression by WT1 peptide-specific CD8+ T cells. Fig. S3. Ex vivo phenotype of granuloma infiltrating cells (GICs). Fig. S4. Ex vivo assessment of regulatory T cells (Treg) in granuloma infiltrating cells (GICs) and PBMCs. Fig. S5. Ex vivo phenotype of checkpoint receptors in granuloma infiltrating cells (GICs) and PBMCs. Fig. S6. Detection of vaccinated peptides in granuloma tissue by mass spectrometry.

10. MOESM8 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 8: Fig. S1. Impact of XS15 on slanMo-mediated T-cell polarization. Fig. S2. Impact of XS15 on slanMo-mediated IFNγ expression by WT1 peptide-specific CD8+ T cells. Fig. S3. Ex vivo phenotype of granuloma infiltrating cells (GICs). Fig. S4. Ex vivo assessment of regulatory T cells (Treg) in granuloma infiltrating cells (GICs) and PBMCs. Fig. S5. Ex vivo phenotype of checkpoint receptors in granuloma infiltrating cells (GICs) and PBMCs. Fig. S6. Detection of vaccinated peptides in granuloma tissue by mass spectrometry.

11. MOESM1 of A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Author

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Chandran, Zelba, Henning, Rusch, Elisa, Gouttefangeas, Cécile, Kowalewski, Daniel, Marco, Moreno, Haen, Sebastian, Walz, Juliane, Yamel Gloria, Bödder, Johanna, Jill-Marie Schertel, Tunger, Antje, Müller, Luise, Kießler, Maximilian, Wehner, Rebekka, Schmitz, Marc, Jakobi, Meike, Schneiderhan-Marra, Nicole, Klein, Reinhild, Laske, Karoline, Artzner, Kerstin, Backert, Linus, Schuster, Heiko, Schwenck, Johannes, Weber, Alexander, Pichler, Bernd, Kneilling, Manfred, Fougère, Christian, Forchhammer, Stephan, Metzler, Gisela, Bauer, Jürgen, Weide, Benjamin, Schippert, Wilfried, Stevanović, Stefan, and Löffler, Markus

Subjects
3. Good health
Abstract

Additional file 1. Supplementary Materials and Methods.

12. EP2/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s.

Author

Cuenca-Escalona J, Bödder J, Subtil B, Sánchez-Sánchez M, Vidal-Manrique M, Sweep MWD, Fauerbach JA, Cambi A, Flórez-Grau G, and de Vries IJM

Abstract

Tumor-derived prostaglandin E2 (PGE2) impairs anti-tumor immunity by priming suppressive functions on various immune cell types, including dendritic cells (DCs). In this way, tumors mediate DC dysfunction and hamper their anti-tumoral activity. PGE2 is known to modulate DC function via signaling through the E-prostanoid receptor type (EP) 2 and EP4. Preclinical studies have demonstrated the therapeutic value of targeting EP2/4 receptor signaling in DCs. Ongoing phase I clinical trials with EP antagonists have shown immunomodulation in cancer patients. However, the systemic drug administration leads to off-target events and subsequent side-effects. To limit the off-target effects of EP targeting, EP2 and EP4 antagonists were encapsulated in polymeric nanoparticles (NPs). In this study we evaluated the efficacy of EP2/4 specific antagonists encapsulated in NPs to protect cDC2s from suppressive effects of tumor-derived PGE2 in different tumor models. We show that tumor-derived PGE2 signals via EP2/4 to mediate the acquisition of a suppressive phenotype of cDC2s. EP2/4 antagonists encapsulated NPs impaired the conversion of cDC2s towards a suppressive state and inhibited the occurrence of suppressive features such as IL-10 production or the ability to expand Tregs. Importantly, the NPs abolished the transition towards this suppressive state in different tumor models: Melanoma-conditioned media, ascites fluid derived from ovarian cancer patients (2D), and upon coculture with colorectal cancer patient-derived organoids (3D). We propose that targeting the PGE2-EP2/4 axis using NPs can achieve immunomodulation in the immune system of cancer patients, alleviate tumor-derived suppression, and thus facilitate the development of potent anti-tumor immunity in cancer patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results